Avacta (LSE:AVCT) has released further data on AVA6103, its FAP-targeted peptide-drug conjugate, including preclinical pancreatic cancer results and an early clinical safety update from the FOCUS-01 trial. Patients are now being treated at a fourth dose level, and the company is working towards an initial efficacy readout in the first half of 2027.
What was announced
On 25 September 2026, Avacta Group plc published an update headed "Further Demonstration of Potential of AVA6103". The announcement coincides with preclinical data presented at the AACR Conference on Pancreatic Cancer, held in San Diego, California, from 25 to 28 September 2026.
AVA6103, also referred to as FAP-Exd, is a peptide-drug conjugate built on the company's pre|CISION platform. It is designed to be activated by fibroblast activation protein (FAP), which the company links to cancer-associated fibroblasts (CAFs) in the tumour environment, and to release an exatecan payload, a topoisomerase I inhibitor, within the tumour.
Clinical update from FOCUS-01
FOCUS-01 is a Phase 1a, first-in-human, multicentre dose escalation trial. It enrols patients with selected tumour types that the company predicts will be sensitive to the exatecan payload. The announcement names cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic ductal adenocarcinoma (PDAC). PDAC patients are enrolled in a separate dose-dense arm, dosed every two weeks (Q2W).
On safety, the company stated that AVA6103 "demonstrated a favorable safety profile and was well tolerated through the first three dose levels up to a payload dose approximately 50% higher than the maximum tolerated dose (MTD) of conventional exatecan."
Avacta added that enrolment is ongoing in both arms, "with patients treated at dose level 4, which represents an absolute dose of payload that is more than double the MTD of conventional exatecan." It said this level approaches the equivalent topoisomerase I inhibitor payload dose of Enhertu, an approved treatment in breast cancer. The announcement's explicit tolerability statement covers the first three dose levels; it does not give a separate tolerability conclusion for dose level 4, where treatment is continuing.
The announcement does not disclose patient numbers, specific adverse events or any efficacy data from the trial.
Preclinical pancreatic cancer data
In patient-derived xenograft (PDX) mouse models of pancreatic cancer, the company reported durable complete and partial tumour responses using the dose-dense regimen. Multiplex immunofluorescence analysis showed high FAP expression in PDAC, with cancer-associated fibroblasts positioned close to blood vessels and tumour cells. The company presents this as supporting the targeting approach, which aims to release the payload in the tumour while limiting systemic exposure.
Preclinical findings in mice do not necessarily predict outcomes in patients.
Management comment
Chief executive Christina Coughlin said: "The preclinical data presented at AACR underscore the significant potential of AVA6103 in addressing the challenges of pancreatic cancer, a disease with limited treatment Options and poor prognosis." She added that the preclinical efficacy data, together with high FAP expression in PDAC, had further increased the company's confidence in AVA6103 as a promising therapeutic candidate.
She added that the first clinical data from FOCUS-01, which she described as "providing clinical evidence consistent with tumor-specific delivery of exatecan by AVA6103", had reinforced the company's confidence in the programme, "and we are now moving towards an initial efficacy readout from the study in H1 2027."
Separately on the same day, Avacta reported that its pre|CISION technology had won an R&D Achievement Award.
What to watch next
The main milestone set out by the company is the initial efficacy readout from FOCUS-01, which Avacta (LSE:AVCT) expects in the first half of 2027. Before then, further updates may cover progress through dose level 4 and beyond, and tolerability at higher payload doses. Details on patient numbers, adverse event profiles and the dose to be taken into later-stage studies were not included in this announcement.






Please wait processing your request...